A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW

Elham Sadeqzadeh; Quan V. Vuong; Chloe D. Goldsmith; Van Tang Nguyen; Deep J. Bhuyan; Trung Thanh Dang; Anita C. Chalmers; Ian A. van Altena; Troy F. Gaston; Natalie Moltschaniwskyj; Michael C. Bowyer; Rick F. Thorne; Judith Weidenhofer; Phuong Thien Thuong; Minh Khoi Nguyen Minh Khoi; Christopher J. Scarlett

A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW

Elham Sadeqzadeh, Quan V. Vuong, Chloe D. Goldsmith, Van Tang Nguyen, Deep J. Bhuyan, Trung Thanh Dang, Anita C. Chalmers, Ian A. van Altena, Troy F. Gaston, Natalie Moltschaniwskyj, Michael C. Bowyer, Rick F. Thorne, Judith Weidenhofer, Phuong Thien Thuong, Minh Khoi Nguyen Minh Khoi, Christopher J. Scarlett

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The diagnosis of pancreatic cancer (PC) has dire consequences as it presents late and is rapidly progressive. Due to the significant heterogeneity, PC is one of the most devastating of human cancers. Treatment options are limited to surgery and/or treatment with gemcitabine, and regardless of intervention, patient outcomes are modest at best. Novel approaches and new treatments are urgently required, and natural product-derived compounds, such as taxol/paclitaxel, irinotecan and gemcitabine provide justification for their continued investigation for novel drug discoveries. Aims: New therapeutic interventions begin in the laboratory. At the University of Newcastle's Central Coast Campus, we are aiming to commission an Australian PC screening facility as part of a PC translational treatment pipeline. Our focus is to exploit the unique evolutionary adaptations that natural products have developed to identify biologically active compounds that target aberrant mechanisms driving pancreatic carcinogenesis.

Original language	English
Pages (from-to)	18-18
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	10
Issue number	S10
Publication status	Published - 2014

Keywords

pancreas
cancer
natural products
drug development
New South Wales

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Sadeqzadeh, E., Vuong, Q. V., Goldsmith, C. D., Nguyen, V. T., Bhuyan, D. J., Dang, T. T., Chalmers, A. C., Altena, I. A. V., Gaston, T. F., Moltschaniwskyj, N., Bowyer, M. C., Thorne, R. F., Weidenhofer, J., Thuong, P. T., Nguyen Minh Khoi, M. K., & Scarlett, C. J. (2014). A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW. Asia-Pacific Journal of Clinical Oncology, 10(S10), 18-18.

@article{9d002f848ae04a18ab68084499162909,

title = "A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW",

abstract = "Background: The diagnosis of pancreatic cancer (PC) has dire consequences as it presents late and is rapidly progressive. Due to the significant heterogeneity, PC is one of the most devastating of human cancers. Treatment options are limited to surgery and/or treatment with gemcitabine, and regardless of intervention, patient outcomes are modest at best. Novel approaches and new treatments are urgently required, and natural product-derived compounds, such as taxol/paclitaxel, irinotecan and gemcitabine provide justification for their continued investigation for novel drug discoveries. Aims: New therapeutic interventions begin in the laboratory. At the University of Newcastle's Central Coast Campus, we are aiming to commission an Australian PC screening facility as part of a PC translational treatment pipeline. Our focus is to exploit the unique evolutionary adaptations that natural products have developed to identify biologically active compounds that target aberrant mechanisms driving pancreatic carcinogenesis.",

keywords = "pancreas, cancer, natural products, drug development, New South Wales",

author = "Elham Sadeqzadeh and Vuong, {Quan V.} and Goldsmith, {Chloe D.} and Nguyen, {Van Tang} and Bhuyan, {Deep J.} and Dang, {Trung Thanh} and Chalmers, {Anita C.} and Altena, {Ian A. van} and Gaston, {Troy F.} and Natalie Moltschaniwskyj and Bowyer, {Michael C.} and Thorne, {Rick F.} and Judith Weidenhofer and Thuong, {Phuong Thien} and {Nguyen Minh Khoi}, {Minh Khoi} and Scarlett, {Christopher J.}",

year = "2014",

language = "English",

volume = "10",

pages = "18--18",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell",

number = "S10",

}

Sadeqzadeh, E, Vuong, QV, Goldsmith, CD, Nguyen, VT, Bhuyan, DJ, Dang, TT, Chalmers, AC, Altena, IAV, Gaston, TF, Moltschaniwskyj, N, Bowyer, MC, Thorne, RF, Weidenhofer, J, Thuong, PT, Nguyen Minh Khoi, MK & Scarlett, CJ 2014, 'A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW', Asia-Pacific Journal of Clinical Oncology, vol. 10, no. S10, pp. 18-18.

TY - JOUR

T1 - A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW

AU - Sadeqzadeh, Elham

AU - Vuong, Quan V.

AU - Goldsmith, Chloe D.

AU - Nguyen, Van Tang

AU - Bhuyan, Deep J.

AU - Dang, Trung Thanh

AU - Chalmers, Anita C.

AU - Altena, Ian A. van

AU - Gaston, Troy F.

AU - Moltschaniwskyj, Natalie

AU - Bowyer, Michael C.

AU - Thorne, Rick F.

AU - Weidenhofer, Judith

AU - Thuong, Phuong Thien

AU - Nguyen Minh Khoi, Minh Khoi

AU - Scarlett, Christopher J.

PY - 2014

Y1 - 2014

N2 - Background: The diagnosis of pancreatic cancer (PC) has dire consequences as it presents late and is rapidly progressive. Due to the significant heterogeneity, PC is one of the most devastating of human cancers. Treatment options are limited to surgery and/or treatment with gemcitabine, and regardless of intervention, patient outcomes are modest at best. Novel approaches and new treatments are urgently required, and natural product-derived compounds, such as taxol/paclitaxel, irinotecan and gemcitabine provide justification for their continued investigation for novel drug discoveries. Aims: New therapeutic interventions begin in the laboratory. At the University of Newcastle's Central Coast Campus, we are aiming to commission an Australian PC screening facility as part of a PC translational treatment pipeline. Our focus is to exploit the unique evolutionary adaptations that natural products have developed to identify biologically active compounds that target aberrant mechanisms driving pancreatic carcinogenesis.

AB - Background: The diagnosis of pancreatic cancer (PC) has dire consequences as it presents late and is rapidly progressive. Due to the significant heterogeneity, PC is one of the most devastating of human cancers. Treatment options are limited to surgery and/or treatment with gemcitabine, and regardless of intervention, patient outcomes are modest at best. Novel approaches and new treatments are urgently required, and natural product-derived compounds, such as taxol/paclitaxel, irinotecan and gemcitabine provide justification for their continued investigation for novel drug discoveries. Aims: New therapeutic interventions begin in the laboratory. At the University of Newcastle's Central Coast Campus, we are aiming to commission an Australian PC screening facility as part of a PC translational treatment pipeline. Our focus is to exploit the unique evolutionary adaptations that natural products have developed to identify biologically active compounds that target aberrant mechanisms driving pancreatic carcinogenesis.

KW - pancreas

KW - cancer

KW - natural products

KW - drug development

KW - New South Wales

UR - https://hdl.handle.net/1959.7/uws:54462

M3 - Article

SN - 1743-7555

VL - 10

SP - 18

EP - 18

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - S10

ER -

A natural product drug discovery pipeline for novel pancreatic cancer therapies : a new cancer research hub for the Hunter region of NSW

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this